

DEMENCIA

- The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. *Supplement to CMJA* 1999;160(12 Suppl):S1-15.
- Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review) *Neurology* 2001;56:1133-1142.
- Practice parameter: Diagnosis of dementia (an evidence-based review) *Neurology* 2001;56:1143-1153.
- Practice parameter: Management of dementia (an evidence-based review) *Neurology* 2001;56:1154-1166.
- American Academy of Neurology: 48th Annual Meeting March 23-30, 1996.
- Conceptos, criterios y recomendaciones para el estudio del paciente con demencia *GENCD de la SEN, 2000*.
- Atención coordinada al paciente con demencia *SEN, SEG, SEP, semFyC, 2000*.
- Consenso Español sobre Demencias *SEP, 2000*.
- Early Alzheimer's Disease Clinical Practice Guideline, Number 19, Consumer Version. Patient and Family Guide. *AHCPR Publication No. 96-0704* September 1996.
- Early Alzheimer's Disease: Recognition and Assessment. Guideline Overview No. 19 *Current as of September 1996. AHCPR Publication No. 97-R123*.
- Recognition and Initial Assessment of Alzheimer's Disease and Related Dementias Clinical Practice Guideline No. 19. *AHCPR Publication No. 97-0702*: November 1996.
- Conferencia de Consenso sobre Demencias y Enfermedad de Alzheimer. *Canarias*.
- Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias of Late Life. American Psychiatric Association published in May 1997.
- 22 Interventions in the management of Behavioural and Psychological Aspects of Dementia. Scottish Intercollegiate Guidelines Network 1998.
- Plan de atención a los enfermos de Alzheimer y otras demencias 1999.
- COUNSELLORS IN PRIMARY CARE. DEC Report No.40 - June 1995. <http://www.epi.bris.ac.uk/~rd/publicat/dec/dec-40.htm>
- Rivastigmine (ExelonTM) in the treatment of senile dementia of the Alzheimer type (SDAT). December 1998 <http://www.epi.bris.ac.uk/~rd/publicat/dec/dec-40.htm> or <http://www.soton.ac.uk/~dec/>. Development & Evaluation Committee Report No.89.
- Screening for Dementia. Guide to Clinical Preventive Services: Second Edition (1996).
- The Primary Care Management of Dementia North of England Evidence Based Guideline Development Project Department of Primary Care and Centre for Health Services Research, University of Newcastle upon Tyne.

- EURODEM <http://www.alzheimer-europe.org>
- COX-2 Inhibitors: A Role in Alzheimer™s Disease? Issues in Emerging Health Technologies, Issue 10 Dec 1999, Canadian Coordinating Office for Health Technology Assessment.
- New Drugs for Alzheimer's Disease Vincent W. Delagarza, M.D., West Virginia University School of Medicine, Morgantown, West Virginia Copyright © 1998 by the American Academy of Family Physicians.
- Drug treatments for Alzheimer's disease. I. A comparative analysis of clinical trials. Wolfson C, Moride Y, Perrault A, Momoli F, Demers L, Oremus M. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2000.
- Drug treatments for Alzheimer's disease. II. A review of outcome measures in clinical trials. Wolfson C, Moride Y, Perrault A, Momoli F, Demers L, Oremus M Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2000.
- Drug treatments for Alzheimer's disease. III. A review of pharmacoeconomic evaluations. Shukla VK, Otten N, Coyle D. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2000. Technology report no 11.
- The efficacy of tacrine and the measurement of outcomes in alzheimer's disease. prepared by Dr. Judith Glennie, FCSHP Pharmaceutical Consultant to CCOHTA *TECHNOLOGY OVERVIEW: PHARMACEUTICALS* ISSUE 5.0 JULY 1997.
- The Growing Challenge of Alzheimer's Disease in Residential Settings. A three-part training program for the staff of retirement communities, assisted living facilities, senior housing developments, case coordination agencies, and area agencies on aging. By Daniel Kuhn, MSW; Anna Ortigara, MS, RN; and David Lindeman, PhD, Rush Alzheimer's Disease Center, Rush Presbyterian-St. Luke's Medical Center, Chicago, Illinois This material was made possible by a grant from The Retirement Research Foundation and is being disseminated by the Alzheimer's Disease Education and Referral Center. © 1999, Rush Alzheimer's Disease Center.
- Rivastigmine was effective and safe in Alzheimer disease *ACP Journal Club*, September/October 1999. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. *BMJ*. 1999 Mar 6;318:633-40.
- Advances in the Treatment of Alzheimer's Disease Philip D. Sloane, M.D., M.P.H., University of North Carolina at Chapel Hill School of Medicine Chapel Hill, North Carolina Copyright © 1998 by the American Academy of Family Physicians.
- Algorithms provided useful information about the course of Alzheimer disease *ACP Journal Club*, September/October 1997. Stern Y, Tang MX, Albert MS, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. *JAMA*. 1997 Mar 12;277:806-12.
- Examples of good practice in the continuum of care *Report by Prof. Mary Marshall Director, Dementia Services Development Centre* Stirling, November 1997. (Copyright (1998): EACH (European Alzheimer Clearing House).
- Social and Economic Cost Calculation of AD and AD Care *Lennart Levi, M.D., Ph.D. Professor Em. of Psychosocial Medicine* 30th November 1997. (Copyright (1998): EACH (European Alzheimer Clearing House).
- Nursing qualifications in different EU member states **FINDINGS: Health Care** By Prof.dr. Joop van Londen (*Project leader*) January 1998 (Copyright (1998): EACH (European Alzheimer Clearing House).

- Quality of care in private sector and NHS facilities for people with dementia: cross sectional survey. Clive Ballard, Jane Fossey, Ramilgan Chithramohan, Robert Howard, Alistair Burns, Peter Thompson, George Tadros, Andrew Fairbairn. *BMJ* VOLUME 323 25 AUGUST 2001;426-7.
- A reevaluation of the duration of survival after the onset of dementia Christina Wolfson, PH.D., David B. Wolfson, PH.D., Masoud Asgharian, PH.D., Cyr Emile M 'LAN, M.SC., Truls ØStbye, M.D., Kenneth Rockwood, M.D., AND D.B. Hogan, M.D., *N Engl J Med* 2001;344:1111-6.
- American College Of Radiology ACR Appropriateness Criteria for Dementia Expert Panel on Neurologic Imaging: Bruce Braffman, MD; Burton P. Drayer, MD; Robert E. Anderson, MD; Patricia C. Davis, MD; Michael D. F. Deck, MD; Anton N. Hasso, MD; Blake A. Johnson, MD; Thomas Masaryk, MD; Stephen J. Pomeranz, MD; David Seidenwurm, MD; Lawrence Tanenbaum, MD; Joseph C; Masdeu, MD, PhD. The complete work of the ACR Appropriateness Criteria™ is available from the American College of Radiology (1891 Preston White Drive, Reston, VA20191-4397) in book format and may be accessed at <http://www.acr.org>
- Educación, demencia y reserva cerebral. Carnero-Pardo C.: *Rev Neurol* 2000; 31: 584-92.
- Drug treatments for Alzheimer's disease: efficacy, outcome measurements and cost-effectiveness. Husereau D, Wolfson C, Shukla VK.: Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2001. Technology Overview no. 4.
- New US guidelines for Alzheimer's disease released. Marilyn Larkin *Lancet* Volume 357, Number 9267 12 May 2001: 1505.
- The challenge of looking after people with dementia *Professional carers need higher expectations and better training and support* Editorials *BMJ* 2001;323:410-1.
- Análisis de las escalas de medición, eficacia de los tratamientos e impacto sociosanitario de la enfermedad de Alzheimer en el País Vasco. Gutiérrez Iglesias M A, Aizpurua Imaz I, Moracho del Río O, y Asua Batarrita J.: *Med Clin* 2000; 114 (Supl): 93-98.
- ¿Son útiles los nuevos fármacos contra la enfermedad de Alzheimer? Carnero-Pardo C.: *Rev Neurol* 2001; 32: 176-9.
- Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL and DeKosky ST.: *Neurology* 2001; 56: 1133-1142.
- Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW Miller B, and Stevens JC.: *Neurology* 2001; 56: 1143-1153.
- Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, and Cummings JL.: *Neurology* 2001; 56: 1154-1166.
- Programa integral de atención psicogeriátrica. S. López-Pousa, J. Serra-Mestres, M. Lozano-Gallego, A. Tron-Estrada, J. Villalta-Franch, J. Garre-Olmo, G. Camps-Rovira, M. Hernández-Ferrándiz, C. Mariscot-Bas, J. Llinàs-Reglà, C. Pujol-Gómez *Rev Neurol* 2000;30(12):1181-1187.

- Guidance on the Use of Donepezil, Rivastigmine and Galantamine for the Treatment of Alzheimer's Disease. National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance No 19. January 2001.

* Otras referencias bibliográficas son citadas en el propio documento y en otros anexos.